|
Product
Type:
Pharmaceutical |
TA:
Cardiovascular & blood
|
|
|
|
|
|
ID No. |
Product Name |
Target / Mechanism of
Action |
Class
of Compound |
Company |
Product
Category |
Indication |
R&D Stage |
Message |
|
B
051 |
TAXUS® Express2™ |
Tubulin |
Paclitaxel- eluting coronary stent |
Boston Scientific |
Medical device with active ingredient |
Coronary artery lesions |
Mar-ket |
Study shows signifant reduction of 9-mth re-narrowing vs. bare-metal stents
in a population with complex lesions
read more |
|
B 054 |
Xact®
carotid stent |
- |
Carotid artery stent |
Abbott |
Medical device |
Carotid artery disease |
Approved
CE |
Received FDA approval of the minimally invasive carotid artery stent to
treat pts at risk of stroke; already launched in EU
read more |
|
B
057 |
Flextome™ Cutting Balloon® dilatation device |
- |
Balloon device with surgical blades (ath-erotomes) |
Boston Scientific |
Medical device |
Coronary artery blockages resistant to PTCA |
Approved |
Received clearance from the FDA to market the device and plans to launch the
product immediately which is already approved 01/2005 in EU
read more |
|
S
104 |
Thelin™
Sitaxsentan sodium |
Endothelin type A receptor antagonism |
Small molecule |
Encysive Pharma-ceuticals |
Small molecule |
Pulmonary arterial hypertension |
MAA
NDA |
Announced interim data of ongoing extension trial after 1 yr of treatment in
support of submission
read more |
|
142 |
ATryn®
Rhu
antithrombin |
Thrombin |
Rhu
antithrombin |
GTC
Bio-therapeutics |
Protein |
Hereditary antithrombin deficiency |
MAA |
EMEA
needs more time for completion of the required site inspection process which
delays the overall review process
read more |
|
S
321 |
MC-4232 |
ACE
inhibition + purinergic receptor antagonism |
Combination of MC-1 and lisinopril |
Medicur |
Small molecule |
Diabetic hypertension |
II |
Announced that combination product MC-4232 met primary hypertension and
metabolic endpoints
read more |
|
S
294 |
Trans NV-04 |
Antioxidant |
Oral
metabolite of isoflavone |
Novogen |
Small molecule |
Patients at risk of cardiovascular events |
Ib |
Study results show significant improvement in blood pressure and arterial
stiffness
read more |
|
Product
Type:
Pharmaceutical |
TA:
Dermatology
|
|
|
|
|
|
ID No. |
Product Name |
Target / Mechanism of
Action |
Class
of Compound |
Company |
Product
Category |
Indication |
R&D Stage |
Message |
|
N
010 |
Oligopeptide-10 |
Antimicrobial and woundhealing properties |
HB64
peptide |
Levlad &
Helix BioMedix |
Cosme-ceuticals |
Acne
|
Mar-ket |
Levlad acquired from Helix BioMedix rights to use its HB64 peptide in
natural and organic cosmetics for use in acne OTC treatment, a US $ 350 mln
market
read more |
|
S
046 |
ISA247 |
immunosuppressive |
Trans-isomer of cyclosporine analogue |
Isotechnika |
Small molecule |
Stable moderate to severe psoriasis |
III |
Announced that 90 % of pts in the phase III trial wish to extend treatment
with study drug
read more |
|
448 |
PRTX-100 |
? |
Protein A (by bacterial fer-mentation) |
Protalex |
Protein |
Pemphigus |
IND |
FDA
released clinical hold on IND; company may start phase I study in healthy
volunteers
read more |
|
Product
Type:
Pharmaceutical |
TA:
Gastrointestinal
|
|
|
|
|
|
ID No. |
Product Name |
Target / Mechanism of
Action |
Class
of Compound |
Company |
Product
Category |
Indication |
R&D Stage |
Message |
|
458 |
Remicade® infliximab |
TNF-alpha |
Rec
chimeric IgG1 mab |
Centocor (J&J) & Schering-Plough & Tanabe Seiyaku |
Antibody |
Moderately to severely active ulcerative colitis |
sBLA |
FDA
approved use of Remicade in ulcerative colitis, the 5th approved
indication
read more |
|
S
324 |
Entereg®
alvimopan |
Peripherally acting mu-opioid receptor antagonism |
Small molecule |
GSK
& Adolor |
Small molecule |
Opioid-induced constipation & related symptoms |
III |
Announced initiation of phase III clinical program which consists of three
studies globally and n=1700 pts
read more |
|
S
300 |
STA-5326 |
IL-12/IL-23 |
Oral
small molecule |
Synta Pharma-ceuticals |
Small molecule |
Active Crohn’s disease |
IIb |
Initiated a rx, pc study evaluating once-daily, oral STA-5326
read more |
|
S
286 |
KOS-2187 |
Motilin agonism |
Erythromycin-based small molecule |
Kosan Biosciences |
Small molecule |
Gastrointestinal motility disorders |
Precl |
Selected KOS-2187 for develop-ment as it is potent, but lacks known side
effects
read more |
